Steris FY2027 Q1: revenue up 7.3%, adjusted EPS $2.59, guidance held
Steris delivered a clean fiscal 2027 first quarter: revenue of $1.49 billion, gross margin up to 45.8%, and adjusted EPS of $2.59 that beat the $2.5272 consensus. Management kept its full-year earnings range but trimmed free cash flow to about $800 million because capital spending is rising. Read the quarter as steady demand, better margins and reaffirmed guidance — with the cash-flow haircut as the one thing to watch.
1 · Expected vs. Actual
Free preview belowGAAP diluted EPS rose to $2.04 from $1.79, and adjusted EPS rose to $2.59 from $2.34. Against the $2.5272 consensus estimate, that is a beat of about $0.06, or 2.5%. Gross margin expanded to 45.8% from 45.1%, the cleanest sign that price and mix, not just cost discipline, did the work.
Revenue was $1.49 billion, up 7.3% from $1.39 billion a year ago, or 6.2% once currency and acquisitions are stripped out. Growth was broad: Healthcare rose 7.6% to $1.05 billion, Life Sciences 8.6% to $146.7 million and AST 5.8% to $297.6 million. Recurring revenue — service and consumables — was $1.23 billion, 82.4% of the total, while capital equipment grew just 3.0% to $263.2 million.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-09-17
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.